Barclays Initiates Coverage On Medtronic with Equal-Weight Rating, Announces Price Target of $95
Barclays analyst Christopher Pasquale initiates coverage on Medtronic (NYSE:MDT) with a Equal-Weight rating and announces Price Target of $95.
Share
Why It Matters
A big bank analyst started watching Medtronic and set a price target of ninety five dollars. This suggests they think the stock is fairly priced right now, neither a great buy nor a bad one.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.